Join a Research Study for an Investigational MDS Treatment! Doctors are testing two study medicines for people with Myelodysplastic Syndromes (MDS) and an IDH1 mutation who haven't had certain treatments before.

The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

Are you newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and looking for treatment options? Our study is evaluating new therapies specifically designed for patients with these conditions. If you have not previously tried an anti-cancer therapy for AML/MDS, this study might be for you!

Do you have a new diagnosis of Leukemia? If so, you may be able to take part in a research study on a new drug called Quizartinib. We want to see if this new drug helps treat Leukemia better. Compensation provided.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Collect Biospecimens from subjects who are newly diagnosed with Acute Myeloid Leukemia (AML)

to see how well the therapy of AK117/placebo combined with Azacitidine fights Higher-risk Myelodysplastic Syndrome and how safe it is.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.